Stroeer shows solid fundamentals but limited growth and unclear impact from the Microsoft-Statista deal amid AI shifts. Find out why SOTDF stock is a hold.

NeoGenomics, Inc. ("NeoGenomics" or the "Company") , a leading provider of oncology diagnostic solutions that enable precision medicine, will debut its PanTracertm Family, a comprehensive suite of ...

Digitalisation also creates the agility needed to pivot when market conditions shift. For instance, automation and ...

Lost Boys is, then, perfectly timed. It takes us on a journey through the manosphere and its population of pick-up artists ...

Also known as selective breeding, artificial selection is the human-guided cousin of evolution by natural selection. Instead ...

Prognostic and predictive impact of next-generation sequencing in metastatic pancreatic ductal adenocarcinoma. First safety analysis of an open-label, single arm phase II trial investigating the ...

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that 12 studies ...

This update will be presented as part of the OPERA-01 trial-in-progress poster at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago, Illinois.

90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclib OPERA-01 trial-in-progress poster to be ...

Explore the impact of movies on business education, from Hollywood to Bollywood, and how they enhance learning outcomes in ...

90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclib OPERA-01 trial-in-progress poster to ...